Lenvatinib and anlotinib: similarities and differences between the two targeted drugs

On the road to anti-cancer treatment, lenvatinib (Lenvatinib) and anlotinib (Anlotinib) are two high-profile targeted therapy drugs. Although they are all anticancer drugs, there are significant differences in their mechanisms of action, therapeutic areas, adverse effects, and cost and accessibility of treatment.

1. Comparison of working principles

The core mechanism of Lenvatinib is that it can inhibit multiple kinases related to tumor growth, such as vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR). In this way, it can cut off the tumor's nutrient supply line——new blood vessels, thereby curbing the spread of cancer cells.

Relatively speaking, anlotinib is a multi-target anti-cancer"warrior". It can not only block VEGFR, but also inhibit epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), etc., to prevent the formation of tumor blood vessels and the proliferation of cancer cells in a multi-pronged approach.

2. Scope of diseases treated

For patients with thyroid cancer and renal cell carcinoma who are inoperable or have poor response to radiotherapy, lenvatinib is like a life-saving straw, providing them with a new treatment option.

Anlotinib is mainly used to attack advanced non-small cell lung cancer (NSCLC) and soft tissue sarcoma (STS), and is especially more effective for patients who are insensitive to traditional chemotherapy and radiotherapy.

3. Observation of adverse reactions

Patients taking lenvatinib may experience symptoms such as fatigue, loss of appetite, discomfort in the hands and feet, fluctuations in blood pressure, and increased protein in the urine. More seriously, it can also lead to cardiovascular problems, liver damage and thyroid disorders.

In contrast, side effects of anlotinib include high blood pressure, hand and foot problems, proteinuria, and general fatigue. The risks of cardiovascular events, liver function damage and bleeding that it may cause cannot be ignored.

4. Wideness of clinical application

Given the remarkable effect of lenvatinib in the treatment of thyroid cancer and renal cell carcinoma, it has been widely adopted and included in medical insurance in many countries such as China, allowing more patients to benefit.

Anlotinib currently focuses on the treatment of advanced non-small cell lung cancer and soft tissue sarcoma. However, its potential for use in other cancer types is still in the process of scientific exploration.

5. Economic Considerations of Drugs

Lenvatinib, as a highly effective targeted drug, is expensive, especially the original drug. Fortunately, in China and other places, medical insurance policies have reduced the financial burden on patients.

On the other hand, as a domestically produced drug, anlotinib is relatively affordable, which is undoubtedly good news for patients with limited financial conditions.

In general, although lenvatinib and anlotinib are both targeted anti-cancer drugs, they show completely different characteristics in many aspects. When making a choice, patients should comprehensively consider their own condition, doctor's advice, drug characteristics, and economic factors to find the treatment plan that best suits them.